BIOQUAL, Inc. (OTC Pink: BIOQ) ( www.bioqual.com ):
| Six Months Ended | Three Months Ended | ||||||||||
|
| 2020 |
|
| 2019 |
|
| 2020 |
|
| 2019 | |
Revenue
| $ | 28,486,183 | $ | 21,290,838 | $ | 13,565,708 | $ | 11,222,962 | ||||
Income Before Income Tax
| $ | 4,562,602 | $ | 3,132,524 | $ | 2,065,614 | $ | 1,258,041 | ||||
Net Income
| $ | 3,228,002 | $ | 2,216,324 | $ | 1,461,414 | $ | 891,841 | ||||
Basic Earnings per Share |
|
|
|
|
|
|
|
| ||||
of Common Stock | $ | 3.61 | $ | 2.48 | $ | 1.63 | $ | 1.00 | ||||
| ||||||||||||
Diluted Earnings per Share |
|
|
|
|
|
|
|
| ||||
of Common Stock | $ | 3.61 | $ | 2.48 | $ | 1.63 | $ | 1.00 | ||||
| ||||||||||||
Weighted Average |
|
|
|
|
|
|
|
| ||||
Number of Shares Outstanding |
|
|
|
|
|
|
|
| ||||
For Basic Earnings Per Share |
| 893,694 |
| 893,416 |
| 893,976 |
| 893,416 | ||||
| ||||||||||||
Weighted Average |
|
|
|
|
|
|
|
| ||||
Number of Shares Outstanding |
|
|
|
|
|
|
|
| ||||
For Diluted Earnings Per Share |
| 893,694 |
| 893,838 |
| 893,976 |
| 893,838 | ||||
|
For more detail related to the fiscal year 2021 unaudited second quarter results, please visit our web site at www.bioqual.com .
Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210122005279/en/
Mark G. Lewis, Ph.D., CEO (240-404-7654)